Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nonalcoholic Fatty Liver Disease and the Heart
Eric Stahl, Devinder S. Dhindsa, Suegene Lee, et al.
Journal of the American College of Cardiology (2019) Vol. 73, Iss. 8, pp. 948-963
Closed Access | Times Cited: 337

Showing 1-25 of 337 citing articles:

NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2020) Vol. 69, Iss. 9, pp. 1691-1705
Open Access | Times Cited: 581
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison, Mustafa R. Bashir, Cynthia D. Guy, et al.
The Lancet (2019) Vol. 394, Iss. 10213, pp. 2012-2024
Closed Access | Times Cited: 580
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
Tracey G. Simon, Björn Roelstraete, Hamed Khalili, et al.
Gut (2020) Vol. 70, Iss. 7, pp. 1375-1382
Open Access | Times Cited: 474
NAFLD and cardiovascular diseases: a clinical review
Philipp Kasper, Anna Martin, Sonja Lang, et al.
Clinical Research in Cardiology (2020) Vol. 110, Iss. 7, pp. 921-937
Open Access | Times Cited: 464
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca, et al.
Metabolism (2020) Vol. 111, pp. 154170-154170
Open Access | Times Cited: 443
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Thomas A. Zelniker, Eugene Braunwald
Journal of the American College of Cardiology (2020) Vol. 75, Iss. 4, pp. 422-434
Closed Access | Times Cited: 417
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
Alessandro Mantovani, Alessandro Csermely, Graziana Petracca, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 11, pp. 903-913
Open Access | Times Cited: 395
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach
Giovanni Targher, Herbert Tilg, Christopher D. Byrne
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 7, pp. 578-588
Open Access | Times Cited: 377
Dietary Fructose and the Metabolic Syndrome
Marja‐Riitta Taskinen, Chris J. Packard, Jan Borén
Nutrients (2019) Vol. 11, Iss. 9, pp. 1987-1987
Open Access | Times Cited: 247
Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis
Ali Aminian, Abbas Al‐Kurd, Rickesha Wilson, et al.
JAMA (2021) Vol. 326, Iss. 20, pp. 2031-2031
Open Access | Times Cited: 241
Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk
Emir Muzurović, Dimitri P. Mikhailidis, Christos S. Mantzoros
Metabolism (2021) Vol. 119, pp. 154770-154770
Closed Access | Times Cited: 198
Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
Jorge Gutiérrez‐Cuevas, Arturo Santos, Juan Armendáriz‐Borunda
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11629-11629
Open Access | Times Cited: 147
Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH
Stephen A. Harrison, Mustafa R. Bashir, Sam E. Moussa, et al.
Hepatology Communications (2021) Vol. 5, Iss. 4, pp. 573-588
Open Access | Times Cited: 145
TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients
Jianqi Zhao, Hongxuan Fan, Ting Wang, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 107
MAFLD: a multisystem disease
Rosaria Maria Pipitone, Carlo Ciccioli, G. Infantino, et al.
Therapeutic Advances in Endocrinology and Metabolism (2023) Vol. 14
Open Access | Times Cited: 107
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
Xiaodong Zhou, Jingjing Cai, Giovanni Targher, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 100
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne, et al.
Hepatology International (2023) Vol. 17, Iss. 4, pp. 773-791
Open Access | Times Cited: 91
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors
Emir Muzurović, Carol Chiung‐Hui Peng, Matthew J. Belanger, et al.
Hypertension (2022) Vol. 79, Iss. 7, pp. 1319-1326
Closed Access | Times Cited: 89
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease
Alessandro Mantovani, Christopher D. Byrne, Giovanni Benfari, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 2, pp. 180-191
Open Access | Times Cited: 83
Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review
Narjes Nasiri‐Ansari, Θεόδωρος Ανδρουτσάκος, Christina‐Maria Flessa, et al.
Cells (2022) Vol. 11, Iss. 16, pp. 2511-2511
Open Access | Times Cited: 76
From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
Andrea Boccatonda, Lorenzo Andreetto, Damiano D’Ardes, et al.
Biomedicines (2023) Vol. 11, Iss. 3, pp. 883-883
Open Access | Times Cited: 65
MAFLD: Exploring the Systemic Effects Beyond Liver.
Utkarsh Dayal, Ujjwal Soni, Sourav Bansal, et al.
Journal of Community Hospital Internal Medicine Perspectives (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Advanced fibrosis is associated with incident cardiovascular disease in patients with non‐alcoholic fatty liver disease
Jacqueline B. Henson, Tracey G. Simon, Alyson Kaplan, et al.
Alimentary Pharmacology & Therapeutics (2020) Vol. 51, Iss. 7, pp. 728-736
Open Access | Times Cited: 128
High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation
Katharina Lechner, Amy L. McKenzie, Nicolle Kränkel, et al.
Metabolic Syndrome and Related Disorders (2020) Vol. 18, Iss. 4, pp. 176-185
Open Access | Times Cited: 115
Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis
Livnat Alon, Bernadette Corica, Valeria Raparelli, et al.
European Journal of Preventive Cardiology (2021) Vol. 29, Iss. 6, pp. 938-946
Open Access | Times Cited: 86
Page 1 - Next Page

Scroll to top